Evidence map›Paper›PMID 36245903›Full record

ArticleRevista panamericana de salud publica = Pan American journal of public health2022

[Fast track patent program for COVID-19 in BrazilProceso rápido de concesión de patentes para enfrentar la COVID-19 en Brasil].

Renata Fittipaldi Pessôa, Érica Guimarães Corrêa, Alexandre Guimarães Vasconcellos

Abstract readEnglish Abstract
In one paragraph

Article in Revista panamericana de salud publica = Pan American journal of public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Renata Fittipaldi PessôaInstituto Nacional da Propriedade Industrial (INPI) Academia de Propriedade Intelectual, Inovação e Desenvolvimento Rio de Janeiro (RJ) Brasil Instituto Nacional da Propriedade Industrial (INPI), Academia de Propriedade Intelectual, Inovação e Desenvolvimento, Rio de Janeiro (RJ), Brasil.
Érica Guimarães CorrêaInstituto Nacional da Propriedade Industrial (INPI) Academia de Propriedade Intelectual, Inovação e Desenvolvimento Rio de Janeiro (RJ) Brasil Instituto Nacional da Propriedade Industrial (INPI), Academia de Propriedade Intelectual, Inovação e Desenvolvimento, Rio de Janeiro (RJ), Brasil.
Alexandre Guimarães VasconcellosInstituto Nacional da Propriedade Industrial (INPI) Divisão de Pós-Graduação e Pesquisa da Academia de Propriedade Intelectual, Inovação e Desenvolvimento Rio de Janeiro (RJ) Brasil Instituto Nacional da Propriedade Industrial (INPI), Divisão de Pós-Graduação e Pesquisa da Academia de Propriedade Intelectual, Inovação e Desenvolvimento, Rio de Janeiro (RJ), Brasil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the objective of stimulating the production and licensing of new technologies, the National Institute of Industrial Property (INPI), the agency responsible for granting patents in Brazil, created a priority or fast track procedure for patent processes related to innovations that can be used against COVID-19. The first effects of this institutional measure are assessed in the present work, based on the identification and analysis of the time elapsed between fast track requests by the Ministry of Health or through petition by the depositors themselves. The results demonstrate that the INPI was able to successfully respond to the public health emergency by granting patents on average 5.3 months after the fast track request, a time considerably shorter than the average required in usual processes.

Indexed as

BrazilCOVID-19intellectual propertyinventionsPatent

Identifiers

PMID36245903
PMCPMC9553014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.